TCT 24: The TRISCEND II Trial
TCT Conference 2024 - Safety and efficacy outcomes of transcatheter tricuspid valve replacement (TTVR) compared to optimal medical therapy for patients with severe tricuspid regurgitation (TR).
Dr Susheel Kodali (Columbia University Medical Center, New York, US) joins us onsite at TCT Conference to discuss the findings from the TRISCEND II Trial (NCT04482062; Edwards Lifesciences).
TRISCEND II is a multi-center, prospective, randomized trial designed to evaluate the safety and effectiveness of the Edwards EVOQUE tricuspid valve replacement system as compared to optimal medical therapy alone in patients with severe TR. 1070 patients were enrolled in the trial and were followed-up at 30 days, 3 months, 6 months, and annually for five years post treatment. The primary outcome measures included TR grade reduction, including KCCQ improvement, NYHA functional class improvement and 6-minute walk test distance improvement, as well as a composite endpoint including all-cause mortality, RVAD implantation or heart transplant, tricuspid valve intervention and heart failure hospitalisations.
One year findings showed that the Edwards EVOQUE system demonstrated superiority in primary endpoints for a patient population with limited treatment options. The Edwards EVOQUE system also led to sustained TR reduction with significant improvements in symptoms, function, and quality of life at one year.
Interview Questions:
1. What is the reasoning behind the TRISCEND II trial?
2. What was the study design and patient population for TRISCEND II?
3. What were the key findings?
4. Were there any surprising or unexpected results?
5. What further study is needed?
Recorded at TCT Conference in Washington, 2024.
Visit Radcliffe Cardiology: https://www.radcliffecardiology.com/
This content is intended for healthcare professionals only.
Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.
Like us on Facebook: / radcliffecardiology
Follow us on X: https://x.com/radcliffeCARDIO
Смотрите видео TCT 24: The TRISCEND II Trial онлайн без регистрации, длительностью часов минут секунд в хорошем качестве. Это видео добавил пользователь Radcliffe Cardiology 01 Ноябрь 2024, не забудьте поделиться им ссылкой с друзьями и знакомыми, на нашем сайте его посмотрели 25 раз и оно понравилось людям.